Acquisition by Aggarwal Gaurav of 5500000 shares of Unicycive Therapeutics at 1000.0 subject to Rule 16b-3
| UNCY Stock | USD 0.68 0.09 15.25% |
Slightly above 57% of all Unicycive Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Unicycive Therapeutics suggests that some traders are interested. Unicycive Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Unicycive Therapeutics' earnings reports, geopolitical events, and overall market trends.
Unicycive |
Filed transaction by Unicycive Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Unicycive Therapeutics Fundamental Analysis
We analyze Unicycive Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Unicycive Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Unicycive Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Unicycive Therapeutics stock to make a market-neutral strategy. Peer analysis of Unicycive Therapeutics could also be used in its relative valuation, which is a method of valuing Unicycive Therapeutics by comparing valuation metrics with similar companies.
Peers
Unicycive Therapeutics Related Equities
| CDIO | Cardio Diagnostics | 3.23 |
| ||
| RNAZ | Transcode Therapeutics | 10.53 |
|
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.